NEW YORK (GenomeWeb News) - Applied Biosystems and BG Medicine are partnering on a research project that will use ABI technology to develop methods for enhancing the scale of biomarker development, ABI said today.
Under the terms of the two-year agreement, BG medicine will integrate ABI technology within its proteomic and metabolomic research pipeline, which BG terms “systems pharmacology.”
BG Medicine focuses on the molecular characterization of disease states and drug response and is already using ABI's mass spectrometers, software, and reagents "in an industrial setting,"
ABI said. Under the current agreement, BG plans to use the same tools to expand the scale of ABI's biomarker discovery and proteomics and metabolomics technologies.
Making these advances "more relevant and applicable on a wider scale," said Laura Lauman, president of ABI's proteomics and small molecule division, "can help transform the process of drug discovery and development.
Financial terms of the agreement were not released.